|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
2
|
Berek JS, Crum C and Friedlander M: Cancer
of the ovary, fallopian tube, and peritoneum. Int J Gynaecol
Obstet. 119(Suppl 2): S118–S129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013.PubMed/NCBI
|
|
4
|
Arvizo RR, Saha S, Wang E, Robertson JD,
Bhattacharya R and Mukherjee P: Inhibition of tumor growth and
metastasis by a self-therapeutic nanoparticle. Proc Natl Acad Sci
USA. 110:6700–6705. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gupta N, Xu Z, El-Sehemy A, Steed H and Fu
Y: Notch3 induces epithelial-mesenchymal transition and attenuates
carboplatin-induced apoptosis in ovarian cancer cells. Gynecol
Oncol. 130:200–206. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ford CE, Jary E, Ma SS, Nixdorf S,
Heinzelmann-Schwarz VA and Ward RL: The Wnt gatekeeper SFRP4
modulates EMT, cell migration and downstream Wnt signalling in
serous ovarian cancer cells. PLoS One. 8:e543622013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yuan H, Kajiyama H, Ito S, et al: ALX1
induces snail expression to promote epithelial-to-mesenchymal
transition and invasion of ovarian cancer cells. Cancer Res.
73:1581–1590. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yoshino H, Enokida H, Itesako T, et al:
Epithelial-mesenchymal transition-related microRNA-200s regulate
molecular targets and pathways in renal cell carcinoma. J Hum
Genet. 58:508–516. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen J, Wang L, Matyunina LV, Hill CG and
McDonald JF: Overexpression of miR-429 induces
mesenchymal-to-epithelial transition (MET) in metastatic ovarian
cancer cells. Gynecol Oncol. 121:200–205. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ke Y, Zhao W, Xiong J and Cao R: miR-149
inhibits non-small-cell lung cancer cells EMT by targeting FOXM1.
Biochem Res Int. 2013:5067312013.PubMed/NCBI
|
|
11
|
Zhou Y, Li Y, Ye J, et al: MicroRNA-491 is
involved in metastasis of hepatocellular carcinoma by inhibitions
of matrix metalloproteinase and epithelial to mesenchymal
transition. Liver Int. 33:1271–1280. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Harazono Y, Muramatsu T, Endo H, et al:
miR-655 is an EMT-suppressive microRNA targeting ZEB1
and TGFBR2. PLoS One. 8:e627572013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gregory PA, Bert AG, Paterson EL, et al:
The miR-200 family and miR-205 regulate epithelial to mesenchymal
transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Paterson EL, Kazenwadel J, Bert AG,
Khew-Goodall Y, Ruszkiewicz A and Goodall GJ: Down-regulation of
the miRNA-200 family at the invasive front of colorectal cancers
with degraded basement membrane indicates EMT is involved in cancer
progression. Neoplasia. 15:180–191. 2013.PubMed/NCBI
|
|
15
|
Croce CM and Calin GA: miRNAs, cancer, and
stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Park SM, Gaur AB, Lengyel E and Peter ME:
The miR-200 family determines the epithelial phenotype of cancer
cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes
Dev. 22:894–907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang D, Sun Y, Hu L, et al: Integrated
analyses identify a master microRNA regulatory network for the
mesenchymal subtype in serous ovarian cancer. Cancer Cell.
23:186–199. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Arora H, Qureshi R and Park WY: miR-506
regulates epithelial mesenchymal transition in breast cancer cell
lines. PLoS One. 8:e642732013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Carvalho J, van Grieken NC, Pereira PM, et
al: Lack of microRNA-101 causes E-cadherin functional deregulation
through EZH2 up-regulation in intestinal gastric cancer. J Pathol.
228:31–44. 2012.PubMed/NCBI
|
|
21
|
Varambally S, Cao Q, Mani RS, et al:
Genomic loss of microRNA-101 leads to overexpression of histone
methyltransferase EZH2 in cancer. Science. 322:1695–1699. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Strillacci A, Valerii MC, Sansone P, et
al: Loss of miR-101 expression promotes Wnt/β-catenin signalling
pathway activation and malignancy in colon cancer cells. J Pathol.
229:379–389. 2013.PubMed/NCBI
|
|
23
|
Parker BC, Annala MJ, Cogdell DE, et al:
The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a
regulation in glioblastoma. J Clin Invest. 123:855–865.
2013.PubMed/NCBI
|
|
24
|
Holmes KM, Annala M, Chua CY, et al:
Insulin-like growth factor-binding protein 2-driven glioma
progression is prevented by blocking a clinically significant
integrin, integrin-linked kinase, and NF-κB network. Proc Natl Acad
Sci USA. 109:3475–3480. 2012.PubMed/NCBI
|
|
25
|
Zhang L, Yang M, Gan L, et al: DLX4
upregulates TWIST and enhances tumor migration, invasion and
metastasis. Int J Biol Sci. 8:1178–1187. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li X, Lu Y, Chen Y, Lu W and Xie X:
MicroRNA profile of paclitaxel-resistant serous ovarian carcinoma
based on formalin-fixed paraffin-embedded samples. BMC Cancer.
13:2162013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cui J, Eldredge JB, Xu Y and Puett D:
MicroRNA expression and regulation in human ovarian carcinoma cells
by luteinizing hormone. PLoS One. 6:e217302011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hu Z, Lin Y, Chen H, et al: MicroRNA-101
suppresses motility of bladder cancer cells by targeting
c-Met. Biochem Biophys Res Commun. 435:82–87. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Caponi S, Funel N, Frampton AE, et al: The
good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155
in pancreatic intraductal papillary mucinous neoplasms. Ann Oncol.
24:734–741. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Semaan A, Qazi AM, Seward S, et al:
MicroRNA-101 inhibits growth of epithelial ovarian cancer by
relieving chromatin-mediated transcriptional repression of
p21waf1/cip1. Pharm Res. 28:3079–3090. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Browne G, Sayan AE and Tulchinsky E: ZEB
proteins link cell motility with cell cycle control and cell
survival in cancer. Cell Cycle. 9:886–891. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vandewalle C, Van Roy F and Berx G: The
role of the ZEB family of transcription factors in development and
disease. Cell Mol Life Sci. 66:773–787. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Peinado H, Olmeda D and Cano A: Snail, Zeb
and bHLH factors in tumour progression: an alliance against the
epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Spoelstra NS, Manning NG, Higashi Y, et
al: The transcription factor ZEB1 is aberrantly expressed in
aggressive uterine cancers. Cancer Res. 66:3893–3902. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pena C, García JM, García V, et al: The
expression levels of the transcriptional regulators p300 and CtBP
modulate the correlations between SNAIL, ZEB1, E-cadherin and
vitamin D receptor in human colon carcinomas. Int J Cancer.
119:2098–2104. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Imamichi Y, König A, Gress T and Menke A:
Collagen type I- induced Smad-interacting protein 1 expression
downregulates E-cadherin in pancreatic cancer. Oncogene.
26:2381–2385. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Elloul S, Elstrand MB, Nesland JM, et al:
Snail, Slug, and Smad-interacting protein 1 as novel parameters of
disease aggressiveness in metastatic ovarian and breast carcinoma.
Cancer. 103:1631–1643. 2005. View Article : Google Scholar
|
|
38
|
Elloul S, Silins I, Tropé CG, Benshushan
A, Davidson B and Reich R: Expression of E-cadherin transcriptional
regulators in ovarian carcinoma. Virchows Arch. 449:520–528. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dahiya N, Sherman-Baust CA, Wang TL, et
al: MicroRNA expression and identification of putative miRNA
targets in ovarian cancer. PLoS One. 3:e24362008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Castilla MÁ, Díaz-Martín J, Sarrió D, et
al: MicroRNA-200 family modulation in distinct breast cancer
phenotypes. PLoS One. 7:e477092012.PubMed/NCBI
|
|
41
|
Hur K, Toiyama Y, Takahashi M, et al:
MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT)
in human colorectal cancer metastasis. Gut. 62:1315–1326. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wei X, Xiang T, Ren G, et al: miR-101 is
down-regulated by the hepatitis B virus × protein and induces
aberrant DNA methylation by targeting DNA methyltransferase 3A.
Cell Signal. 25:439–446. 2013.
|
|
43
|
Rao ZY, Cai MY, Yang GF, et al: EZH2
supports ovarian carcinoma cell invasion and/or metastasis via
regulation of TGF-β1 and is a predictor of outcome in ovarian
carcinoma patients. Carcinogenesis. 31:1576–1583. 2010.
|
|
44
|
Lu C, Bonome T, Li Y, et al: Gene
alterations identified by expression profiling in tumor-associated
endothelial cells from invasive ovarian carcinoma. Cancer Res.
67:1757–1768. 2007. View Article : Google Scholar : PubMed/NCBI
|
